- Home
- ULS vs NBIX Comparison
ULS vs NBIX Comparison
Compare ULS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ULS | NBIX |
|---|---|---|
| Founded | 1894 | 1992 |
| Country | United States | United States |
| Employees | 15094 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 14.4B |
| IPO Year | 2024 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ULS | NBIX |
|---|---|---|
| Price | $76.90 | $155.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 19 |
| Target Price | $78.75 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 1.1M | 969.9K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | 10.58 | ★ 12.44 |
| EPS | 1.67 | ★ 4.19 |
| Revenue | ★ $3,003,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | $7.18 | $23.76 |
| Revenue Next Year | $5.56 | $18.01 |
| P/E Ratio | $45.86 | ★ $37.10 |
| Revenue Growth | 6.68 | ★ 19.61 |
| 52 Week Low | $48.54 | $84.23 |
| 52 Week High | $91.95 | $157.67 |
Technical Indicators
Market Signals| Indicator | ULS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.51 | 64.81 |
| Support Level | $76.05 | $150.26 |
| Resistance Level | $91.66 | $154.35 |
| Average True Range (ATR) | 2.52 | 4.16 |
| MACD | -1.72 | 1.07 |
| Stochastic Oscillator | 3.46 | 93.25 |
Price Performance
Historical ComparisonAbout ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.